What ALKS 7290 ADHD Trial Results Mean For Alkermes (ALKS) Stock
simplywall.st
The ALKS 7290 trial results provide additional support for Alkermes' orexin platform by demonstrating potential use in ADHD, expanding beyond narcolepsy and influencing future Phase 2 trial design. However, near-term stock performance remains heavily dependent on the success of existing products like Vivitrol, Aristada, and Lybalvi, as rising R&D costs and orexin investment could pressure margins and profitability. The appointment of Anne C. Whitaker as an independent director adds strategic board experience that may help manage the balance between pipeline expansion and financial discipline as Alkermes scales its neuroscience portfolio.
All articles from 23 September 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.